Martial Caillaud1, Nipa H Patel2, Alyssa White2, Mackinsey Wood2, Katherine M Contreras2, Wisam Toma2, Yasmin Alkhlaif2, Jane L Roberts2, Tammy H Tran2, Asti B Jackson2, Justin Poklis2, David A Gewirtz2, M Imad Damaj3. 1. Department of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Virginia Commonwealth University, USA. Electronic address: martial.caillaud@vcuhealth.org. 2. Department of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Virginia Commonwealth University, USA. 3. Department of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Virginia Commonwealth University, USA; Translational Research Initiative for Pain and Neuropathy, Virginia Commonwealth University, USA. Electronic address: m.damaj@vcuhealth.org.
Abstract
BACKGROUND AND PURPOSE: Paclitaxel, a widely used anti-cancer drug, is frequently associated with prolonged and severe peripheral neuropathies (PIPN), associated with neuroinflammation. Currently, PIPN effective treatments are lacking. Peroxisome Proliferator-Activated Receptor-α (PPAR-⍺) can modulate inflammatory responses. Thus, the use of PPAR-⍺ agonists, such as fibrates (fenofibrate and choline-fenofibrate), currently used in dyslipidemia treatment, could represent an interesting therapeutic approach in PIPN. EXPERIMENTAL APPROACH: Our studies tested the efficacy of fenofibrate (150 mg/kg, daily, i.p.) and choline fenofibrate (60 mg/kg daily, p.o.) in reversing and preventing the development of PIPN (paclitaxel: 8 mg/kg, i.p., every other day for 4 days) in male and female C57BL/6J mice. Mechanical and cold hypersensitivity, conditioned place preference, sensory nerve action potential (SNAP), as well as the expression of PPAR-⍺, TNF-⍺, IL-1β and IL-6 mRNA were evaluated. KEY RESULTS: While fenofibrate treatment partially reversed and prevented the development of mechanical hypersensitivity, this was completely reversed and prevented by choline-fenofibrate. Both fibrates were able to completely reverse and prevent cold hypersensitivity induced by paclitaxel. The reduction of SNAP amplitude induced by paclitaxel was also reversed by both fenofibrate and choline-fenofibrate. Our results indicate that suppression of paclitaxel-induced hypersensitivity by fibrates involves the regulation of PPAR-⍺ expression and decrease neuroinflammation in DRG. Finally, the co-treatment of Paclitaxel and fenofibric acid (fibrates active metabolite) was tested on different cancer cell lines, no decrease in the antitumoral effect of paclitaxel was observed. CONCLUSIONS AND IMPLICATIONS: Taken together, our results show for the first time the therapeutic potential (prevention and reversal) of fibrates in PIPN and opens to a potential pharmacological repurposing of these drugs.
BACKGROUND AND PURPOSE: Paclitaxel, a widely used anti-cancer drug, is frequently associated with prolonged and severe peripheral neuropathies (PIPN), associated with neuroinflammation. Currently, PIPN effective treatments are lacking. Peroxisome Proliferator-Activated Receptor-α (PPAR-⍺) can modulate inflammatory responses. Thus, the use of PPAR-⍺ agonists, such as fibrates (fenofibrate and choline-fenofibrate), currently used in dyslipidemia treatment, could represent an interesting therapeutic approach in PIPN. EXPERIMENTAL APPROACH: Our studies tested the efficacy of fenofibrate (150 mg/kg, daily, i.p.) and choline fenofibrate (60 mg/kg daily, p.o.) in reversing and preventing the development of PIPN (paclitaxel: 8 mg/kg, i.p., every other day for 4 days) in male and female C57BL/6J mice. Mechanical and cold hypersensitivity, conditioned place preference, sensory nerve action potential (SNAP), as well as the expression of PPAR-⍺, TNF-⍺, IL-1β and IL-6 mRNA were evaluated. KEY RESULTS: While fenofibrate treatment partially reversed and prevented the development of mechanical hypersensitivity, this was completely reversed and prevented by choline-fenofibrate. Both fibrates were able to completely reverse and prevent cold hypersensitivity induced by paclitaxel. The reduction of SNAP amplitude induced by paclitaxel was also reversed by both fenofibrate and choline-fenofibrate. Our results indicate that suppression of paclitaxel-induced hypersensitivity by fibrates involves the regulation of PPAR-⍺ expression and decrease neuroinflammation in DRG. Finally, the co-treatment of Paclitaxel and fenofibric acid (fibrates active metabolite) was tested on different cancer cell lines, no decrease in the antitumoral effect of paclitaxel was observed. CONCLUSIONS AND IMPLICATIONS: Taken together, our results show for the first time the therapeutic potential (prevention and reversal) of fibrates in PIPN and opens to a potential pharmacological repurposing of these drugs.
Authors: Elisa Burgos; Diego Gómez-Nicola; David Pascual; María Isabel Martín; Manuel Nieto-Sampedro; Carlos Goicoechea Journal: Eur J Pharmacol Date: 2012-02-21 Impact factor: 4.432
Authors: Antônio Carlos P Oliveira; Caryne M Bertollo; Leonardo Tadeu S Rocha; Elias B Nascimento; Karina A Costa; Márcio M Coelho Journal: Eur J Pharmacol Date: 2007-01-19 Impact factor: 4.432
Authors: Ye Rim Cho; Ji Hee Lim; Min Young Kim; Tae Woo Kim; Bo Young Hong; Yong-Soo Kim; Yoon Sik Chang; Hye Won Kim; Cheol Whee Park Journal: PLoS One Date: 2014-01-02 Impact factor: 3.240
Authors: Martial Caillaud; Danielle Thompson; Wisam Toma; Alyssa White; Jared Mann; Jane L Roberts; John W Bigbee; David A Gewirtz; M Imad Damaj Journal: Pharmaceutics Date: 2022-06-17 Impact factor: 6.525
Authors: Oshri Avraham; Alexander Chamessian; Rui Feng; Lite Yang; Alexandra E Halevi; Amy M Moore; Robert W Gereau; Valeria Cavalli Journal: Pain Date: 2022-03-31 Impact factor: 7.926
Authors: Melissa E Lenert; Amanda Avona; Katherine M Garner; Luz R Barron; Michael D Burton Journal: Endocrinology Date: 2021-08-01 Impact factor: 5.051
Authors: Anukriti Sharma; Ken B Johnson; Bihua Bie; Emily E Rhoades; Alper Sen; Yuri Kida; Jennifer Hockings; Alycia Gatta; Jacqueline Davenport; Connie Arcangelini; Jennifer Ritzu; Jennifer DeVecchio; Ron Hughen; Mei Wei; G Thomas Budd; N Lynn Henry; Charis Eng; Joseph Foss; Daniel M Rotroff Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec